Calidi Biotherapeutics, Inc. Common Stock (CLDI)

Specificity Inc. (OTCID: SPTY), a next-generation digital marketing firm, has regained its status as a fully reporting SEC current filer—marking a key milestone as it continues to revolutionize audience targeting across digital platforms. Known for eliminating bots and irrelevant impressions, Specificity’s proprietary ad tech delivers precision-targeted ads across display, social, and Connected TV (CTV) to the same verified, high-intent audiences —maximizing ROI and minimizing waste.

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients and not others. This challenge has made it difficult for these immunotherapies to be widely used since it isn’t easy to predict who will benefit and yet the treatments are currently very expensive .

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus for treating soft tissue sarcoma. The designation provides opportunities for expedited development, including priority review and accelerated approval. CLD-201, which received IND clearance in April, will enter a Phase 1 trial evaluating safety and efficacy in sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma. Chief Medical Officer Guy Travis Clifton, M.D., said the milestone validates CLD-201’s potential to deliver durable, transformational treatment for patients with advanced tumors.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery platforms, will implement a 1-for-12 reverse stock split of its common stock effective August 5, 2025. Shares will begin trading on a split-adjusted basis on the NYSE American under the existing ticker “CLDI,” with a new CUSIP of 320703 408. The reverse split, approved by shareholders on July 9 and ratified by the board on July 11, is intended to optimize market dynamics, expand investor appeal and align trading conditions with shareholder interests. Every 12 pre-split shares will convert into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level. The action will proportionately adjust outstanding options, warrants and equity plan shares but will not affect the par value or the number of authorized shares.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing targeted genetic medicine therapies, will host an investor webinar on July 24, 2025, at 4:15 p.m. ET. Led by CEO Eric Poma, Ph.D., the event will showcase Calidi’s RedTail(TM) platform, a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. Preclinical data on lead candidate CLD-401 showed tumor elimination and immune memory activation. The company is progressing toward an IND filing and pursuing strategic pharma partnerships to support commercialization. A Q&A session will follow the presentation.

Lung cancer, one of the most common types of cancer, has for a long time been known to largely develop among smokers. However, recent studies have established that around one quarter of people diagnosed with lung cancer has never smoked. This has baffled the scientific community as there was no clear explanation why such a significant proportion of lung cancer patients didn’t have a history of smoking.

Findings from a recent study suggest that the herpes virus can be modified into an effective treatment for some types of advanced melanoma. Conducted by researchers from the University of Southern California’s Keck Medicine of USC, the clinical trial looked into the feasibility of deploying cancer-fighting herpes virus against advanced skin cancers.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company’s initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds to support its clinical and pre-clinical programs, operations and working capital.

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

NetworkNewsWire Editorial Coverage : Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades. By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi’s technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators, including Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ImmunityBio Inc. (NASDAQ: IBRX) , Crispr Therapeutics AG (NASDAQ: CRSP) and…

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

NetworkNewsWire Editorial Coverage : An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON) , Roche (OTCQX: RHHBY) and…

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END

While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end of 2026. Calidi also opened an IND for its intratumoral virotherapy, CLD-201, with Phase I trials anticipated by year-end. The company ended Q1 with $10.6 million in cash and a significantly reduced burn rate, aiming to rapidly advance its pipeline while enhancing shareholder value.

An ongoing clinical trial at the Comprehensive Cancer Center at UC Davis seeks to find out whether fermented wheat germ could help cancer patients undergoing immunotherapy have better outcomes and live full lives, or even beat cancer.

Newly published research has uncovered why most smokers don’t develop lung cancer even after years or even decades of consuming tobacco. Even though tobacco is one of the main causes of lung cancer, containing various chemicals that can trigger the disease by damaging DNA, only a small number of smokers actually develop the deadly condition. According to researchers, some cigarette smokers seem to possess certain defense systems that prevent them from developing lung cancer even as they continue to expose themselves to tobacco.

Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of growth. His extensive background in oncology, successful track record in fundraising and strategic partnerships, and comprehensive understanding of the biotech landscape position him to effectively steer Calidi’s innovative therapies through clinical development and toward commercialization.”

Many young celebrities have recently announced that they have been diagnosed with breast cancer . This is a clear pointer to the public that cases of this disease among younger women not yet 50 years of age are rising in America.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical models. Calidi has further advanced this technology with CLD-401, its first therapeutic candidate from the RedTail platform. New data presented at the meeting demonstrate a novel genetic modification in which a chimeric CD55 receptor is incorporated into the envelope shielding the virus. Because CD55 receptor expression acts as a robust inhibitor of complement, this modification further enhances the virus’s resistance to rapid clearance by the humoral immune system following intravenous administration.”

A research team whose leadership is based in South Korea has developed an AI model for predicting how cancer patients will respond to immunotherapy. Designed to improve the precision of treatment in colorectal and gastric cancer, the AI model could provide physicians with a significantly more accurate tool for customizing therapies.